Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

NCT01283594 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: Tozadenant (SYN115) 60 mg BID
DRUG: Placebo
DRUG: Levodopa (L-dopa)
DRUG: Tozadenant (SYN115) 120 mg BID
DRUG: Tozadenant (SYN115) 180 mg BID
DRUG: Tozadenant (SYN115) 240 mg BID

Sponsor

Biotie Therapies Inc.